Dr. Voorhees on Managing TRAEs for Patients With Multiple Myeloma

Video

Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses optimal management of treatment-related adverse events (TRAEs) for patients with multiple myeloma.

Peter Voorhees, MD, hematology, medical oncology, Carolinas HealthCare System, discusses optimal management of treatment-related adverse events (TRAEs) for patients with multiple myeloma.

Data from a SWOG study showed that the addition of bortezomib (Velcade) to a lenalidomide (Revlimid)/dexamethasone doublet significantly increases toxicity; peripheral neuropathy is a significant concern in these patients, Voorhees explains. The use of subcutaneous bortezomib will help lower the risk of neuropathy. Additionally, many physicians have started moving toward a modified RVd (lenalidomide, bortezomib, and dexamethasone)—type platform for older patients who may be more prone to these AEs.

For patients 75 years of age or older, or for patients with brittle diabetes or congestive heart failure, Voorhees says he is more likely to use a 20-mg dose of dexamethasone as opposed to a 40-mg dose. This allows researchers to adjust the schedule and mode of administration with regard to bortezomib.

Related Videos
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD
Minesh Mehta, MD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,